Why is Panacea Biotec falling/rising?

As of 18-Nov, Panacea Biotec Ltd is experiencing a decline in its stock price, currently at Rs 374.50, reflecting a decrease of Rs 15.3 or 3.93%. The stock has underperformed its sector by 3.31% today and has been on a downward trend for the last three days, accumulating a total loss of 7.32% during this period. Additionally, the stock has shown negative returns over the past week and month, with declines of 5.52% and 15.90%, respectively. The company is trading below all its moving averages, indicating a bearish trend. Despite a rise in delivery volume by 108.42% on 17 November, the overall financial health of the company is concerning, with significant operating losses and a weak ability to service its debt.
In the broader market context, while the Sensex has gained 0.96% over the past week, Panacea Biotec's performance has been notably poor, highlighting a stark contrast between the stock and the benchmark. The company's long-term fundamentals are weak, with net sales declining at an annual rate of -0.13% and an alarming operating profit drop of -218.34% over the last five years. Recent negative financial results, including a substantial fall in profit before tax and profit after tax, further exacerbate the stock's risk profile. The increasing participation of institutional investors, who now hold 2.86% of the company, may provide some support, but the overall outlook remains negative due to the company's financial struggles.